In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae
Open Access
- 1 May 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (5) , 921-922
- https://doi.org/10.1128/aac.29.5.921
Abstract
The in vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) was compared with the activities of five other orally absorbable antimicrobial agents against 100 clinical isolates of Haemophilus influenzae. Roxithromycin MICs were generally twofold to fourfold higher than those of erythromycin; the MIC for 90% of the strains for roxithromycin was 8 micrograms/ml.This publication has 7 references indexed in Scilit:
- Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogensAntimicrobial Agents and Chemotherapy, 1985
- In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugsAntimicrobial Agents and Chemotherapy, 1983
- Penetration of Amoxicillin, Cefaclor, Erythromycin-Sulfisoxazole, and Trimethoprim-Sulfamethoxazole into the Middle Ear Fluid of Patients with Chronic Serous Otitis MediaThe Journal of Infectious Diseases, 1982
- Concentrations of antimicrobial agents in middle ear fluid, saliva and tearsInternational Journal of Pediatric Otorhinolaryngology, 1981
- ERYTHROMYCIN CONCENTRATIONS IN MIDDLE EAR EXUDATESPediatrics, 1971